IGF-1 DES vs C-peptide
Head-to-head comparison of IGF-1 DES (Des(1-3) Insulin-like Growth Factor 1) and C-peptide (Connecting peptide (C-peptide)) — benefits, dosing, side effects, research data, and where to buy.
| Property | IGF-1 DES | C-peptide |
|---|---|---|
| Category | Growth Hormone | Pain Management |
| Full Name | Des(1-3) Insulin-like Growth Factor 1 | Connecting peptide (C-peptide) |
| Molecular Weight | 7365 Da | 3020.3 Da |
| Half-Life | ~20-30 minutes | ~20-30 min |
| Amino Acids | 67 | 31 |
| Typical Dose | — | no approved analgesic dose|research-only |
| Route | — | IV|subQ |
| Purity | >98% | ≥98% |
| Studies Count | 65 | 46 |
| Research Status | Active Research | Pre-clinical |
IGF-1 DES Benefits
- ✓Highly potent localized muscle growth, enhanced protein synthesis, satellite cell proliferation, does not bind to IGFBPs, rapid onset
C-peptide Benefits
- ✓diabetic neuropathy research
- ✓nerve function support
- ✓possible analgesic effect
IGF-1 DES Dosing
50-150 mcg per injection site bilaterally post-workout. 4-6 week cycles due to potency. Multiple daily injections in research.
C-peptide Dosing
0.5-1.0 mg/day in research|route varies by protocol
IGF-1 DES Side Effects
- ⚠Hypoglycemia (dose-dependent), localized swelling, shorter duration limits systemic exposure compared to IGF-1 LR3.
C-peptide Side Effects
- ⚠injection-site reactions
- ⚠unknown long-term safety
Research Overview
IGF-1 DES
Missing first three amino acids (Gly-Pro-Glu) eliminates IGFBP binding, resulting in 100% bioavailable IGF-1R stimulation. Activates PI3K/Akt/mTOR for protein synthesis and satellite cell proliferation.
C-peptide
C-peptide is not an approved analgesic, but multiple studies have examined its effects on peripheral nerve blood flow and neuropathy outcomes. The strongest relevance is in diabetic neuropathic pain rather than migraine.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.